HIV-leukemia patient receives rare transplant

Doctors at the University of Minnesota Amplatz Children's Hospital are hopefully a promising bone marrow transplant will cure a boy diagnosed with HIV and leukemia.

http://www.inforum.com/event/article/id/397528/

Research and Markets: Atripla (HIV) - Forecast and Market Analysis to 2022

... of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces ...

http://www.businesswire.com/news/topix/20130424005766/en

Research and Markets: Quad 2 (HIV) - Forecast and Market Analysis to 2022

... of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces ...

http://www.businesswire.com/news/topix/20130424005739/en

Research and Markets: 572-Trii (HIV) - Forecast and Market Analysis to 2022

... of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces ...

http://www.businesswire.com/news/topix/20130424005732/en

Research and Markets: Dolutegravir (HIV) - Forecast and Market Analysis to 2022

... of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces ...

http://www.businesswire.com/news/topix/20130424005728/en

HIV-leukemia patient receives rare transplant

Doctors at the University of Minnesota Amplatz Children's Hospital are hopefully a promising bone marrow transplant will cure a boy diagnosed with HIV and leukemia.

http://www.10tv.com/content/stories/apexchange/2013/04/24/mn--hiv-leukemia-transplant.html

Janssen Submits Approval Requests for New Hepatitis C Drug Simeprevir

Janssen has submitted requests for approval in the U.S. and Europe for its investigational HCV protease inhibitor simeprevir as an addition to interferon-based therapy for people with genotype 1 or 4 chronic hepatitis C virus infection.

http://www.hivandhepatitis.com/hepatitis-c/hepatitis-c-topics/hcv-treatment/4065-janssen-submits-approval-requests-for-new-hepatitis-c-drug-simeprevir